Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud of ...

Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...

Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug ‌designing software. Integration of Lilly's ...

CEO Ramy Farid highlighted "very solid progress in the first half of 2025" with total revenue of $54.8 million in the second quarter, a 16% increase year-over-year. Software revenue reached $40.5 ...

Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc. (NASDAQ:SDGR) from Neutral to Buy, with a $24 price ...

Mr. Aklian joins Schrödinger from Certara, where he served as senior vice president, global software sales. In this role, Mr. Aklian led a global team of professionals in sales and operations and ...